DOCSLIB.ORG

Table 2 Genes with Higher Mrna Levels in the Control Group

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 2 Genes with Higher Mrna Levels in the Control Group Table 2 Genes with higher mRNA levels in the control group Bos taurus Homo sapiens Accession q -value Gene description of best BLAST hit Gene symbol gene ID gene ID number Fold up (%) Score (d) Cyc Function/biological process H.s. alpha 1,4-galactosyltransferase A4GALT 53947 NM_017436 -4,2 0,00 -4,54 glycosphingolipid biosynthesis B.t. mRNA for similar to alpha 2 actin ACTA2 281593 59 AB098797 -2,7 0,00 -4,38 x cytoskeleton B.t. actin, beta ACTB 280979 60 NM_173979 -2,2 0,25 -2,67 x cytoskeleton B.t. a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 4 ADAMTS4 286806 9507 NM_181667 -5,0 0,22 -2,88 ECM remodeling B.t. annexin A2 ANXA2 282689 302 NM_174716 -2,4 0,21 -2,87 x ECM remodeling B.t. dynein heavy chain ; dynein, axonemal, heavy polypeptide 11 [H.s.] Bv1 (DNAH11) 497208 8701 U63924 -2,3 0,50 -2,43 cytoskeleton B.t. calbindin 3, (vitamin D-dependent calcium binding protein) CALB3 (S100G) 281658 795 NM_174257 -3,1 0,21 -2,78 calcium absorption H.s. chondroitin polymerizing factor CHPF 79586 NM_024536 -2,5 0,00 -3,41 ECM remodeling H.s. cytoskeleton-associated protein 4 CKAP4 10970 NM_006825 -5,0 0,00 -3,44 cytoskeleton organization B.t. claudin 10 CLDN10 506545 9071 BT020910 -7,8 1,27 -1,97 x cell adhesion H.s. collagen, type I, alpha 1 COL1A1 282187 1277 NM_000088 -4,4 0,00 -3,86 x ECM protein B.t. collagen, type I, alpha 2 COL1A2 282188 1278 NM_174520 -3,2 0,20 -2,86 x ECM protein B.t. type III pro-collagen gene COL3A1 282190 1281 L47641 -3,1 0,08 -3,32 x ECM protein H.s. collagen, type IV, alpha 2 COL4A2 497192 1284 NM_001846 -3,5 0,00 -5,49 x ECM protein H.s. collagen, type VI, alpha 1 COL6A1 282193 1291 NM_001848 -2,3 0,00 -3,37 x ECM protein H.s. collagen, type VI, alpha 2 COL6A2 282194 1292 NM_058175 -2,0 0,12 -3,21 x ECM protein H.s. collagen, type VI, alpha 3 COL6A3 1293 NM_004369 -5,8 0,00 -4,35 x ECM protein H.s. collagen, type XV, alpha 1 COL15A1 1306 NM_001855 -4,2 0,03 -4,66 x ECM protein B.t. cDNA; LCCL domain containing cysteine-rich secretory protein 2 [H.s.] CRISPLD2 83716 CK832702 -2,9 0,00 -4,44 unknown H.s. deiodinase, iodothyronine, type II DIO2 494548 1734 NM_013989 -2,3 0,00 -3,78 thyroid hormone activation B.t. DnaJ (Hsp40) homolog, subfamily B, member 11 DNAJB11 506316 51726 NM_001034268 -2,3 0,22 -2,79 protein folding H.s. dystonin DST 667 NM_183380 -2,1 0,67 -2,08 cytoskeleton organization H.s. deltex 4 homolog (Drosophila) DTX4 23220 BC015592 -4,4 0,00 -4,46 protein ubiquitination? B.t. estrogen receptor 1 alpha ESR1 281145 2099 AY656813 -3,0 0,06 -3,74 transcription factor H.s. mRNA; cDNA DKFZp762L0811; fatty acid desaturase 1 [H.s.] FADS1 533107 3992 AL834479 -2,4 0,12 -2,91 fatty acid metabolism H.s. fibulin 1 FBLN1 2192 NM_006487 -2,2 0,67 -2,19 x ECM, cell adhesion H.s. hypothetical protein FLJ14054 FLJ14054 79614 NM_024563 -6,2 0,00 -5,19 unknown B.t. filamin A FLNA 281165 2316 AY072716 -3,3 0,00 -4,34 cytoskeleton organization H.s. growth arrest and DNA-damage-inducible, gamma GADD45G 10912 NM_006705 -9,8 0,00 -8,10 differentiation, coactivator of ESR1? similar to B.t. gastrin-releasing peptide (94%) GRP-like* 280809 2922 NM_178319 -2,2 0,11 -3,13 signal transduction B.t. partial mRNA for heat shock 70kDa protein 5 (grp78 gene) HSPA5 281829 3309 AJ586431 -2,6 0,14 -2,92 ER chaperone 4123573 BARC 8BOV B.t. cDNA; H.s. IBR domain containing 2 IBRDC2 255488 CN789149 -2,5 0,39 -2,38 target of p53, E3 ubiquitin ligase H.s. insulin-like growth factor 1 (somatomedin C) IGF1 281239 3479 NM_000618 -2,4 0,22 -2,79 growth factor H.s. tubulin, alpha, ubiquitous K-ALPHA-1 10376 NM_006082 -2,4 0,00 -3,54 cytoskeleton H.s. KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 KDELR2 11014 NM_006854 -2,1 0,22 -2,62 sorting receptor H.s. KIAA2010 KIAA2010 55671 NM_032560 -3,0 0,12 -2,91 unknown PREDICTED: B.t. similar to Laminin beta-1 chain precursor (Laminin B1 chain) LAMB1 520030 3912 XM_598260 -2,1 0,39 -2,39 cell adhesion B.t. lactate dehydrogenase A LDHA 281274 3939 NM_174099 -2,0 0,31 -2,49 anaerobic glycolysis H.s. melanoma antigen family D, 1 MAGED1 512562 9500 NM_001005333 -2,9 0,12 -3,12 x apoptosis-related Bos grunniens metallothionein-2 MT2A 404070 4502 AY513745 -6,3 0,31 -2,54 metal ion binding H.s. myosin, light polypeptide kinase MYLK 338037 4638 NM_053025 -3,0 0,06 -3,61 cytoskeleton organization B.t. oxytocin receptor OXTR 281371 5021 NM_174134 -120 0,00 -9,32 luteolysis H.s. polo-like kinase 2 PLK2 10769 NM_006622 -6,6 0,00 -6,38 signal transduction H.s. protease, serine, 11 (IGF binding) PRSS11 (HTRA1) 282326 5654 NM_002775 -2,7 0,00 -4,09 x signal transduction PREDICTED: B.t. similar to transcription factor RAM2 (LOC514631) RAM2 (CDCA7L) 514631 55536 XM_592513 -2,3 0,31 -2,56 x transcription factor H.s. retinoic acid receptor responder 1 RARRES1 5918 NM_206963 -2,4 0,12 -3,01 x inhibition of proliferation B.t. retinol binding protein 4, plasma RBP4 281444 5950 S65585 -2,8 0,04 -3,46 retinol carrier H.s. syndecan 2 SDC2 615785 6383 NM_002998 -2,6 0,52 -2,35 cell-matrix interaction PREDICTED: B.t. similar to Sec61 alpha subunit homolog (LOC505064) SEC61A1 505064 29927 XM_581292 -2,1 0,27 -3,44 x transport H.s. serine (or cysteine) proteinase inhibitor, clade H, member 1 SERPINH1 871 NM_001235 -2,7 0,00 -3,54 x collagen maturation H.s. splicing factor, arginine/serine-rich 10 SFRS10 615156 6434 NM_004593 -2,5 0,00 -3,71 pre-mRNA splicing H.s. SPARC related modular calcium binding 2 SMOC2 64094 NM_022138 -3,3 0,17 -2,87 ECM protein H.s. SRY (sex determining region Y)-box 4 SOX4 6659 NM_003107 -3,2 0,12 -2,98 x transcription factor B.t. secreted protein, acidic, cysteine-rich [osteonectin] SPARC 282077 6678 NM_174464 -3,0 0,00 -3,79 x ECM protein H.s. stanniocalcin 1 STC1 338078 6781 NM_003155 -2,5 1,03 -1,68 luteinization inhibitor H.s. stimulated by retinoic acid gene 6 homolog STRA6 64220 NM_022369 -3,5 0,00 -3,84 RA signaling Bovine preprotachykinin B gene, exon 7; H.s. tachykinin 3 TAC3 281513 6866 M14352 -3,0 1,03 -1,73 vasodilator B.t. thrombospondin THBS 281530 7057 NM_174196 -4,7 0,39 -2,37 x ECM protein B.t. thrombospondin 2 THBS2 338092 7058 NM_176872 -2,5 0,00 -4,13 ECM protein B.t. tissue inhibitor of metalloproteinase 1 TIMP1 282092 7076 NM_174471 -5,8 0,00 -3,95 ECM remodeling H.s. transmembrane, prostate androgen induced TMEPAI 56937 NM_020182 -4,7 0,00 -4,62 TGF-beta induced H.s. tenascin C (hexabrachion) TNC 3371 NM_002160 -13,5 0,02 -3,97 x ECM protein H.s. tubulin, beta polypeptide TUBB 203068 NM_178014 -3,0 0,03 -3,94 x cytoskeleton B.t. tubulin, beta polypeptide (TUBB) TUBB (TUBB2A) 281555 7280 NM_001003900 -2,3 0,10 -3,76 cytoskeleton B.t. tubulin, beta polypeptide; H.s. tubulin, beta 6 TUBB6 84617 NM_001003900 -3,0 0,00 -4,09 cytoskeleton H.s. unc-5 homolog B UNC5B 219699 NM_170744 -3,4 0,85 -1,89 signal transduction B.t. cDNA; zinc finger protein 703 ZNF703 80139 CO887790 -2,0 0,67 -2,19 unknown H.s. zyxin ZYX 617259 7791 NM_003461 -2,3 0,22 -2,74 cell adhesion PREDICTED: B.t. hypothetical LOC509824 509824 XM_586871 -2,2 0,94 -1,84 unknown B.t. cDNA; Chr. 8 60817035-60817713 DT837144 -5,3 0,64 -2,17 H.s. Homo sapiens , B.s. Bos taurus ; Gene symbols given in parentheses represent Homo sapiens gene name if differing; * no official gene symbol; Cyc genes previously detected as up-regulated in the bovine endometrium at oestrus during oestrous cycle (Bauersachs 2005).
Load more

Recommended publications
  • Synergistic Genetic Interactions Between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models
    BASIC RESEARCH www.jasn.org Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models Rory J. Olson,1 Katharina Hopp ,2 Harrison Wells,3 Jessica M. Smith,3 Jessica Furtado,1,4 Megan M. Constans,3 Diana L. Escobar,3 Aron M. Geurts,5 Vicente E. Torres,3 and Peter C. Harris 1,3 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD) are genetically distinct, with ADPKD usually caused by the genes PKD1 or PKD2 (encoding polycystin-1 and polycystin-2, respectively) and ARPKD caused by PKHD1 (encoding fibrocys- tin/polyductin [FPC]). Primary cilia have been considered central to PKD pathogenesis due to protein localization and common cystic phenotypes in syndromic ciliopathies, but their relevance is questioned in the simple PKDs. ARPKD’s mild phenotype in murine models versus in humans has hampered investi- gating its pathogenesis. Methods To study the interaction between Pkhd1 and Pkd1, including dosage effects on the phenotype, we generated digenic mouse and rat models and characterized and compared digenic, monogenic, and wild-type phenotypes. Results The genetic interaction was synergistic in both species, with digenic animals exhibiting pheno- types of rapidly progressive PKD and early lethality resembling classic ARPKD. Genetic interaction be- tween Pkhd1 and Pkd1 depended on dosage in the digenic murine models, with no significant enhancement of the monogenic phenotype until a threshold of reduced expression at the second locus was breached.
    [Show full text]
  • S100 Calcium-Binding Protein S100 Proteins
    S S100 Calcium-Binding Protein experiments showed the S100 protein fraction consti- tuted two different dimeric species comprised of two ▶ S100 Proteins b protomers (S100B) or an a, b heterodimer (Isobe et al. 1977). Early members of the S100 protein family were frequently given suffixes based on their localiza- tion or molecular size and included S100P (placental), S100 Proteins S100C (cardiac or calgizzarin), p11 (11 kDa), and MRP8/MRP14 (myeloid regulatory proteins, 8 and Brian R. Dempsey, Anne C. Rintala-Dempsey and 14 kDa). In 1993, initial genetic studies showed that Gary S. Shaw six of the S100 genes were clustered on chromosome Department of Biochemistry, The University of 1q21 (Engelkamp et al. 1993), a number that has Western Ontario, London, ON, Canada expanded since. Based on this observation most of the proteins were renamed according to the physical order they occupy on the chromosome. These include Synonyms S100A1 (formerly S100a), S100A2 (formerly S100L), S100A10 (p11), S100A8/S100A14 (MRP8/MRP14). S100 calcium-binding protein A few S100 proteins are found on other chromosomes including S100B (21q21). Currently there are 27 known S100 family members: S100A1-A18, S100B, S100 Protein Family Members S100G, S100P, S100Z, trichohylin, filaggrin, filaggrin- 2, cornulin, and repetin (Table 1). S100A1, S100A2, S100A3, S100A4, S100A5, S100A6, S100A7, S100A8, S100A9, S100A10, S100A11, S100A12, S100A13, S100A14, S100A15, S100A16, Role of S100 Proteins in Calcium Signaling S100B, S100P, S100G, S100Z, trichohylin, filaggrin, filaggrin-2,
    [Show full text]
  • Ciliopathies Gene Panel
    Ciliopathies Gene Panel Contact details Introduction Regional Genetics Service The ciliopathies are a heterogeneous group of conditions with considerable phenotypic overlap. Levels 4-6, Barclay House These inherited diseases are caused by defects in cilia; hair-like projections present on most 37 Queen Square cells, with roles in key human developmental processes via their motility and signalling functions. Ciliopathies are often lethal and multiple organ systems are affected. Ciliopathies are London, WC1N 3BH united in being genetically heterogeneous conditions and the different subtypes can share T +44 (0) 20 7762 6888 many clinical features, predominantly cystic kidney disease, but also retinal, respiratory, F +44 (0) 20 7813 8578 skeletal, hepatic and neurological defects in addition to metabolic defects, laterality defects and polydactyly. Their clinical variability can make ciliopathies hard to recognise, reflecting the ubiquity of cilia. Gene panels currently offer the best solution to tackling analysis of genetically Samples required heterogeneous conditions such as the ciliopathies. Ciliopathies affect approximately 1:2,000 5ml venous blood in plastic EDTA births. bottles (>1ml from neonates) Ciliopathies are generally inherited in an autosomal recessive manner, with some autosomal Prenatal testing must be arranged dominant and X-linked exceptions. in advance, through a Clinical Genetics department if possible. Referrals Amniotic fluid or CV samples Patients presenting with a ciliopathy; due to the phenotypic variability this could be a diverse set should be sent to Cytogenetics for of features. For guidance contact the laboratory or Dr Hannah Mitchison dissecting and culturing, with ([email protected]) / Prof Phil Beales ([email protected]) instructions to forward the sample to the Regional Molecular Genetics Referrals will be accepted from clinical geneticists and consultants in nephrology, metabolic, laboratory for analysis respiratory and retinal diseases.
    [Show full text]
  • Rage (Receptor for Advanced Glycation End Products) in Melanoma
    RAGE (RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS) IN MELANOMA PROGRESSION A Dissertation Submitted to the Graduate Faculty of the North Dakota State University of Agriculture and Applied Science By Varsha Meghnani In Partial Fulfillment for the Degree of DOCTOR OF PHILOSOPHY Major Department: Pharmaceutical Sciences May 2014 Fargo, North Dakota North Dakota State University Graduate School Title RAGE (RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS) IN MELANOMA PROGRESSION By VARSHA MEGHNANI The Supervisory Committee certifies that this disquisition complies with North Dakota State University’s regulations and meets the accepted standards for the degree of DOCTOR OF PHILOSOPHY SUPERVISORY COMMITTEE: ESTELLE LECLERC Chair BIN GUO STEPHEN O’ROURKE JANE SCHUH Approved: 5/22/2014 JAGDISH SINGH Date Department Chair ABSTRACT The Receptor for Advanced Glycation End Products (RAGE) and its ligands are expressed in multiple cancer types and are implicated in cancer progression. Our lab has previously reported higher transcript levels of RAGE and S100B in advanced staged melanoma patients. The contribution of RAGE in the pathophysiology of melanoma has not been well studied. Based on previous reports, we hypothesized that RAGE, when over-expressed in melanoma cells, promotes melanoma progression. To study the pathogenic role of RAGE in melanoma, a primary melanoma cell line, WM115, was selected and stably transfected with full length RAGE (FL_RAGE) to generate a model cell line over-expressing RAGE (WM115_RAGE). WM266, a sister cell line of WM115, originated from a metastatic tumor of the same patient was used as a metastatic control cell line in the study. After assessing the expression levels of RAGE in the transfected cells, the influence of RAGE on their cellular properties was examined.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • De Novo, Systemic, Deleterious Amino Acid Substitutions Are Common in Large Cytoskeleton‑Related Protein Coding Regions
    BIOMEDICAL REPORTS 6: 211-216, 2017 De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton‑related protein coding regions REBECCA J. STOLL1, GRACE R. THOMPSON1, MOHAMMAD D. SAMY1 and GEORGE BLANCK1,2 1Department of Molecular Medicine, Morsani College of Medicine, University of South Florida; 2Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA Received June 13, 2016; Accepted October 31, 2016 DOI: 10.3892/br.2016.826 Abstract. Human mutagenesis is largely random, thus large Introduction coding regions, simply on the basis of probability, represent relatively large mutagenesis targets. Thus, we considered Genetic damage is largely random and therefore tends to the possibility that large cytoskeletal-protein related coding affect the larger, functional regions of the human genome regions (CPCRs), including extra-cellular matrix (ECM) more frequently than the smaller regions (1). For example, coding regions, would have systemic nucleotide variants that a systematic study has revealed that cancer fusion genes, on are not present in common SNP databases. Presumably, such average, are statistically, significantly larger than other human variants arose recently in development or in recent, preceding genes (2,3). The large introns of potential cancer fusion genes generations. Using matched breast cancer and blood-derived presumably allow for many different productive recombina- normal datasets from the cancer genome atlas, CPCR single tion opportunities, i.e., many recombinations that would allow nucleotide variants (SNVs) not present in the All SNPs(142) for exon juxtaposition and the generation of hybrid proteins. or 1000 Genomes databases were identified. Using the Protein Smaller cancer fusion genes tend to be associated with the rare Variation Effect Analyzer internet-based tool, it was discov- types of cancer, for example EWS RNA binding protein 1 in ered that apparent, systemic mutations (not shared among Ewing's sarcoma.
    [Show full text]
  • Next Generation Massively Parallel Sequencing of Targeted
    ARTICLE Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: Implications for application to clinical testing Jonathan S. Berg, MD, PhD1,2, James P. Evans, MD, PhD1,2, Margaret W. Leigh, MD3, Heymut Omran, MD4, Chris Bizon, PhD5, Ketan Mane, PhD5, Michael R. Knowles, MD2, Karen E. Weck, MD1,6, and Maimoona A. Zariwala, PhD6 Purpose: Advances in genetic sequencing technology have the potential rimary ciliary dyskinesia (PCD) is an autosomal recessive to enhance testing for genes associated with genetically heterogeneous Pdisorder involving abnormalities of motile cilia, resulting in clinical syndromes, such as primary ciliary dyskinesia. The objective of a range of manifestations including situs inversus, neonatal this study was to investigate the performance characteristics of exon- respiratory distress at full-term birth, recurrent otitis media, capture technology coupled with massively parallel sequencing for chronic sinusitis, chronic bronchitis that may result in bronchi- 1–3 clinical diagnostic evaluation. Methods: We performed a pilot study of ectasis, and male infertility. The disorder is genetically het- four individuals with a variety of previously identified primary ciliary erogeneous, rendering molecular diagnosis challenging given dyskinesia mutations. We designed a custom array (NimbleGen) to that mutations in nine different genes (DNAH5, DNAH11, capture 2089 exons from 79 genes associated with primary ciliary DNAI1, DNAI2, KTU, LRRC50, RSPH9, RSPH4A, and TX- dyskinesia or ciliary function and sequenced the enriched material using NDC3) account for only approximately 1/3 of PCD cases.4 the GS FLX Titanium (Roche 454) platform. Bioinformatics analysis DNAH5 and DNAI1 account for the majority of known muta- was performed in a blinded fashion in an attempt to detect the previ- tions, and the other genes each account for a small number of ously identified mutations and validate the process.
    [Show full text]
  • Olfactory Dysfunction Is Worse in Primary Ciliary Dyskinesia Compared
    Thorax Online First, published on February 28, 2018 as 10.1136/thoraxjnl-2017-210661 Brief communication Thorax: first published as 10.1136/thoraxjnl-2017-210661 on 28 February 2018. Downloaded from Olfactory dysfunction is worse in primary ciliary dyskinesia compared with other causes of chronic sinusitis in children Massimo Pifferi,1 Andrew Bush,2 Michele Rizzo,1 Alessandro Tonacci,3 Maria Di Cicco,1 Martina Piras,1 Fabrizio Maggi,4 Giulia Paiola,5 Angela Michelucci,6 Angela Cangiotti,7 Diego Peroni,1 Davide Caramella,8 Attilio L Boner5 ► Additional material is ABSTRact respiratory infection for ≥4 weeks. nNO was meas- published online only. To view Cilia have multiple functions including olfaction. We ured using standard methodology.9 please visit the journal online Olfactory function was assessed using the Sniffin’ (http:// dx. doi. org/ 10. 1136/ hypothesised that olfactory function could be impaired thoraxjnl- 2017- 210661). in primary ciliary dyskinesia (PCD). Olfaction, nasal nitric Sticks Extended Test (Burghart Medizintechnik, GmbH, Wedel, Germany), which consists of three 1 oxide (nNO) and sinus CT were assessed in patients with Department of Paediatrics, PCD and non-PCD sinus disease, and healthy controls different subtests, assessing the olfactory sensitivity University Hospital of Pisa, (threshold), discrimination and identification.10 Pisa, Italy (no CT scan). PCD and non-PCD patients had similar 2Imperial College and Royal severity of sinus disease. Despite this, defective olfaction All patients underwent unenhanced CT scans. Brompton Hospital, London, UK was more common in patients with PCD (P<0.0001) The degree of paranasal sinuses inflammation was 3Institute of Clinical Physiology, assessed using a modified Lund-Mackay system.11 and more severe in patients with PCD with major National Research Council of Full details of all methods are online (see online Italy (IFC-CNR), Pisa, Italy Transmission Electron Microscopy (TEM) abnormalities.
    [Show full text]
  • Prognostic Values of S100 Family Members in Ovarian Cancer Patients Yang Bai1,2,3†, Liang-Dong Li4,5†, Jun Li1,2,3 and Xin Lu1,2,3,6*
    Bai et al. BMC Cancer (2018) 18:1256 https://doi.org/10.1186/s12885-018-5170-3 RESEARCH ARTICLE Open Access Prognostic values of S100 family members in ovarian cancer patients Yang Bai1,2,3†, Liang-Dong Li4,5†, Jun Li1,2,3 and Xin Lu1,2,3,6* Abstract Objective: Exhibiting high consistence in sequence and structure, S100 family members are interchangeable in function and they show a wide spectrum of biological processes, including proliferation, apoptosis, migration, inflammation and differentiation and the like. While the prognostic value of each individual S100 in ovarian cancer is still elusive. In current study, we investigated the prognostic value of S100 family members in the ovarian cancer. Methods: We used the Kaplan Meier plotter (KM plotter) database, in which updated gene expression data and survival information are from 1657 ovarian cancer patients, to assess the relevance of individual S100 family mRNA expression to overall survival in various ovarian cancer subtypes and different clinicopathological features. Results: It was found that high expression of S100A2 (HR = 1.18, 95%CI: 1.04–1.34, P = 0.012), S100A7A (HR = 1.3, 95%CI: 1. 04–1.63, P = 0.02),S100A10 (HR = 1.2, 95%CI: 1.05–1.38, P = 0.0087),and S100A16 (HR = 1.23, 95%CI: 1–1.51, P = 0.052) were significantly correlated with worse OS in all ovarian cancer patients, while the expression of S100A1 (HR = 0.87, 95%CI: 0. 77–0.99, P = 0.039), S100A3 (HR = 0.83, 95%CI: 0.71–0.96, P = 0.0011), S100A5 (HR = 0.84, 95%CI: 0.73–0.97, P = 0.017), S100A6 (HR = 0.84, 95%CI: 0.72–0.98, P = 0.024), S100A13 (HR = 0.85, 95%CI:0.75–0.97, P = 0.014) and S100G (HR = 0.86, 95%CI: 0.74–0.99, P = 0.041) were associated with better prognosis.
    [Show full text]
  • This Electronic Thesis Or Dissertation Has Been Downloaded from Explore Bristol Research
    This electronic thesis or dissertation has been downloaded from Explore Bristol Research, http://research-information.bristol.ac.uk Author: Al Ahdal, Hadil Title: Investigating the role of miR-21 in adult neurogenesis General rights Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License. A copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode This license sets out your rights and the restrictions that apply to your access to the thesis so it is important you read this before proceeding. Take down policy Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research. However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity, defamation, libel, then please contact [email protected] and include the following information in your message: •Your contact details •Bibliographic details for the item, including a URL •An outline nature of the complaint Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible. Investigating the role of miR-21 in adult neurogenesis Hadil Mohammad Al Ahdal Faculty of Health Sciences Bristol Medical School A dissertation submitted to the University of Bristol in accordance with the requirements for award of the degree of Doctor of Philosophy in the Faculty of Health Sciences, Bristol Medical School 64,598 words Abstract MicroRNAs (miRNAs) are a class of small non-coding RNAs that act as post- transcriptional regulators and play important roles in neurodegenerative diseases and brain disorders (Nelson et al.
    [Show full text]
  • Ciliary Dyneins and Dynein Related Ciliopathies
    cells Review Ciliary Dyneins and Dynein Related Ciliopathies Dinu Antony 1,2,3, Han G. Brunner 2,3 and Miriam Schmidts 1,2,3,* 1 Center for Pediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg University Faculty of Medicine, Mathildenstrasse 1, 79106 Freiburg, Germany; [email protected] 2 Genome Research Division, Human Genetics Department, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 KL Nijmegen, The Netherlands; [email protected] 3 Radboud Institute for Molecular Life Sciences (RIMLS), Geert Grooteplein Zuid 10, 6525 KL Nijmegen, The Netherlands * Correspondence: [email protected]; Tel.: +49-761-44391; Fax: +49-761-44710 Abstract: Although ubiquitously present, the relevance of cilia for vertebrate development and health has long been underrated. However, the aberration or dysfunction of ciliary structures or components results in a large heterogeneous group of disorders in mammals, termed ciliopathies. The majority of human ciliopathy cases are caused by malfunction of the ciliary dynein motor activity, powering retrograde intraflagellar transport (enabled by the cytoplasmic dynein-2 complex) or axonemal movement (axonemal dynein complexes). Despite a partially shared evolutionary developmental path and shared ciliary localization, the cytoplasmic dynein-2 and axonemal dynein functions are markedly different: while cytoplasmic dynein-2 complex dysfunction results in an ultra-rare syndromal skeleto-renal phenotype with a high lethality, axonemal dynein dysfunction is associated with a motile cilia dysfunction disorder, primary ciliary dyskinesia (PCD) or Kartagener syndrome, causing recurrent airway infection, degenerative lung disease, laterality defects, and infertility. In this review, we provide an overview of ciliary dynein complex compositions, their functions, clinical disease hallmarks of ciliary dynein disorders, presumed underlying pathomechanisms, and novel Citation: Antony, D.; Brunner, H.G.; developments in the field.
    [Show full text]
  • Computational Analyses of Small Molecules Activity from Phenotypic Screens
    Computational analyses of small molecules activity from phenotypic screens Azedine Zoufir Hughes Hall This dissertation is submitted for the degree of Doctor of Philosophy July 2018 Declaration This thesis is submitted as the result of my own work and includes nothing which is the outcome of work done in collaboration except where specifically indicated in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the preface and specified in the text. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. This dissertation does not exceed the word limit of 60,000 words. Azedine Zoufir July 2018 Summary Title: Computational analyses of small molecules activity from phenotypic screens Author: Azedine Zoufir Drug discovery is no longer relying on the one gene-one disease paradigm nor on target-based screening alone to discover new drugs. Phenotypic-based screening is regaining momentum to discover new compounds since those assays provide an environment closer to the physiological state of the disease and allow to better anticipate off-target effects and other factors that can limit the efficacy of the drugs. However, uncovering the mechanism of action of the compounds active in those assays relies on in vitro techniques that are expensive and time- consuming.
    [Show full text]